07-478
Anti-SNF2β/BRG1 Antibody
serum, Upstate®
Synonyme(s) :
Probable global transcription activator SNF2L4, ATP-dependent helicase SMARCA4, SNF2-beta, BRG-1, Mitotic growth and transcription activator, Brahma protein homolog 1, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A m
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
eCl@ss :
32160702
Nomenclature NACRES :
NA.41
Produits recommandés
Source biologique
rabbit
Niveau de qualité
Forme d'anticorps
serum
Type de produit anticorps
primary antibodies
Clone
polyclonal
Espèces réactives
rat, mouse, human
Conditionnement
antibody small pack of 25 μL
Fabricant/nom de marque
Upstate®
Technique(s)
immunoprecipitation (IP): suitable
western blot: suitable
Isotype
IgG
Numéro d'accès NCBI
Numéro d'accès UniProt
Conditions d'expédition
ambient
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... SMARCA4(6597)
Description générale
The SNF2 family of proteins are ATP dependant chromatin remodeling enzymes. The gene encoding this protein is also refered to as SMARCA4.
The SWI-SNF complex is involved in the activation of transcription via the remodeling of nucleosome structure in an ATP-dependent manner. Brm (also designated SNF2α) and Brg-1 (also designated SNF2β) are the ATPase subunits of the mammalian SWI-SNF complex. Brm, Brg-1, Ini1 (integrase interactor 1, also designated SNF5), BAF155 (also designated SRG3) and BAF170 are thought to comprise the functional core of the SWI-SNF complex. Addition of Ini1, BAF155 and BAF170 to Brg-1 appears to increase remodeling activity. Other complex subunits are thought to play regulatory roles. hSNF2L and hSNF2H both appear to be homologs of Drosophila ISWI, a Brm related ATPase that is present in chromatin remodeling complexes other than SWI/SNF, including the NURF (nucleosome remodeling factor).
Spécificité
This antibody recognizes the Near N-Terminus of SNF2B
Immunogène
GST-tagged recombinant protein corresponding to the Near N-Terminus of human SNF2β.
Application
Immunocytochemistry Analysis: A 1:250 dilution from a representative lot detected BRG1 in HeLa cells.
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Cell Cycle, DNA Replication & Repair
Transcription Factors
Cell Cycle, DNA Replication & Repair
Transcription Factors
Use Anti-SNF2β/BRG1 Antibody (rabbit polyclonal antibody) validated in IP, WB to detect SNF2β/BRG1 also known as Probable global transcription activator SNF2L4, ATP-dependent helicase SMARCA4, SNF2-beta, BRG-1.
Qualité
Evaluated by Western Blotting in HELA NE cell lysate.
Western Blotting Analysis: A 1:4,000 dilution of this antibody detected SNF2B/BRG1 in 10 µg of HELA NE cell lysate.
Western Blotting Analysis: A 1:4,000 dilution of this antibody detected SNF2B/BRG1 in 10 µg of HELA NE cell lysate.
Description de la cible
200 kDa
Forme physique
Rabbit polyclonal in buffer containing with 0.05% sodium azide with 30% glycerol.
Unpurified
Stockage et stabilité
Maintain for 2 years at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Remarque sur l'analyse
Control
Positive Antigen Control: Catalog #12-309, Hela cell nuclear extract. Add an equal volume of Laemmli reducing sample buffer to 10 μL of extract and boil for 5 minutes to reduce the preparation. Load 20 μg of reduced extract per lane for minigels.
Positive Antigen Control: Catalog #12-309, Hela cell nuclear extract. Add an equal volume of Laemmli reducing sample buffer to 10 μL of extract and boil for 5 minutes to reduce the preparation. Load 20 μg of reduced extract per lane for minigels.
Autres remarques
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Informations légales
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
En option
Réf. du produit
Description
Tarif
Code de la classe de stockage
10 - Combustible liquids
Classe de danger pour l'eau (WGK)
WGK 1
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Activation of ATP-binding cassette transporter A1 transcription by chromatin remodeling complex.
Huuskonen, J; Vishnu, M; Fielding, PE; Fielding, CJ
Arteriosclerosis, Thrombosis, and Vascular Biology null
Cutting edge: SWISNF mediates antisense Igh transcription and locus-wide accessibility in B cell precursors.
Osipovich OA, Subrahmanyam R, Pierce S, Sen R, Oltz EM
Journal of immunology (Baltimore, Md. : 1950) (1950)
Joel Vincent Fair et al.
BMC developmental biology, 16(1), 27-27 (2016-08-04)
The Hedgehog (HH) signalling pathway regulates cardiomyogenesis in vivo and in differentiating P19 embryonal carcinoma (EC) cells, a mouse embryonic stem (mES) cell model. To further assess the transcriptional role of HH signalling during cardiomyogenesis in stem cells, we studied
Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.
Witkowski, Leora, et al.
Nature Genetics, 46, 438-443 (2014)
Petar Jelinic et al.
Nature genetics, 46(5), 424-426 (2014-03-25)
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare, highly aggressive form of ovarian cancer primarily diagnosed in young women. We identified inactivating biallelic SMARCA4 mutations in 100% of the 12 SCCOHT tumors examined. Protein studies confirmed
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique